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Context: Polycystic ovary syndrome (PCOS), the most common endocrinopathy in women, is char-
acterizedbyhigh levels of secretionof luteinizinghormone (LH) and testosterone. Currently, there
is no treatment licensed specifically for PCOS.
Objective: To investigate whether a targeted therapy would decrease LH pulse frequency in
womenwith PCOS, subsequently reducing serum LH and testosterone concentrations and thereby
presenting a novel therapeutic approach to the management of PCOS.
Design: Double-blind, double-dummy, placebo-controlled, phase 2 trial.
Settings: University hospitals and private clinical research centres.
Participants: Women with PCOS aged 18–45 years.
Intervention: AZD4901 (a specific neurokinin-3 [NK3] receptor antagonist) at a dose of 20, 40, or
80 mg/day or matching placebo for 28 days.
Mainoutcomemeasure:Change frombaseline in the areaunder the LH serumconcentration–time
curve over 8 hours (AUC) on day 7 relative to placebo.
Results:Of a total of 67 randomized patients, 65were evaluable. On day 7, the following baseline-
adjusted changes relative to placebo were observed in patients receiving AZD4901 80 mg/day: (1)
a reduction of 52.0% (95% CI: 29.6–67.3%) in LH AUC; (2) a reduction of 28.7% (95% CI: 13.9–
40.9%) in total testosterone concentration; and (3) a reduction of 3.55 LH pulses/8 hours (95% CI:
2.0–5.1) (all nominal P  .05).
Conclusions: The NK3 receptor antagonist AZD4901 specifically reduced LH pulse frequency and
subsequently serum LH and testosterone concentrations, thus presenting NK3 receptor antago-
nism as a potential approach to treating the central neuroendocrine pathophysiology of PCOS.
Results: from this phase 2 clinical trial demonstrate the potential for a selective neurokinin-3
receptor antagonist to target the neuroendocrine pathophysiology of luteinizing hormone hy-
persecretion and hyperandrogenism in PCOS.
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Polycystic ovary syndrome (PCOS) is themost commonendocrinopathy in women, and it affects approxi-
mately 5%–10% of women of reproductive age (1, 2).
Different consensus groups have developed different def-
initions of PCOS. Depending on which definition is used,
diagnosis is based on the presence of some or all of the
following: chronic anovulation, polycystic appearance of
the ovaries, and excessive testosterone secretion (hyperan-
drogenemia) or activity (hyperandrogenism) (3–5). PCOS
is associated with several clinical presentations, such as
menstrual dysfunction, infertility, hirsutism, acne, obe-
sity, and metabolic syndrome (4, 6). In the long term,
women with PCOS also have an increased risk of type 2
diabetes mellitus and potentially cardiovascular disease
(6, 7). Treatment involves management of symptoms,
chronic suppression of the hypothalamic–pituitary axis
(eg, antiandrogens and exogenous sex steroids) or meta-
bolic modulation (eg, metformin), often with therapies
used off-label (6, 8). There is an unmet need to develop a
targeted, safe, and effective treatment that addresses the
underlying central endocrinopathy.
The pathophysiological mechanisms underpinning
PCOSaremultifactorial, includingdevelopmental factors,
metabolic factors (eg, hyperinsulinemia) and genetic fac-
tors (9–11). Nevertheless, PCOS is associated with an in-
crease in luteinizing hormone (LH) pulse amplitude and
pulse frequency, which is likely driven by increased pul-
satile secretion of gonadotropin-releasing hormone
(GnRH) (12). This excess of pituitary LH secretion results
in failure of ovulation and increased ovarian testosterone
production (12). Recent discoveries suggest that the kiss-
peptin-neurokininB (NKB)–GnRHpathway is the pivotal
regulator of LH secretion (13, 14). Indeed, patients with
genetically impaired NKB signaling have low baseline LH
secretion and low LH pulse frequency (15, 16). Thus,
pharmacologicalNKBblockademaybe a useful approach
to targeting the central pathophysiology of LH hyperse-
cretion and hyperandrogenism in PCOS.
In mammals, there are three tachykinin receptors, of
which the neurokinin-3 (NK3) receptor appears to be as-
sociated with a reproductive regulatory role through its
ligand NKB (17). AZD4901 is a high-affinity antagonist
of the humanNK3 receptor (18). Itwas initially developed
for schizophrenia in 2007–2010 (as AZD2624) but did
not meet its developmental efficacy goals for that indica-
tion (19). In common with other NK3 receptor antago-
nists, however, AZD2624 reduced LH and testosterone
concentrations in healthy volunteers and patients without
endocrine or reproductive disorders (18). At the time, a
reproductive role for NKB was yet to be elucidated (15).
Since then, much evidence has accrued that suggests that
NKBhas a central role in the generationofGnRHand thus
LH pulsatility (13). It is therefore thought that AZD4901
regulates pituitary LH and gonadal testosterone via mod-
ulation of GnRH pulsatility.
PCOS is aheterogeneousdisorder,withmultiplepatho-
physiological mechanisms (eg, insulin resistance) in addi-
tion toLHhypersecretioncontributing to itsdevelopment.
In this randomized controlled trial (RCT), our interven-
tion (AZD4901) specifically targets LH hypersecretion.
We hypothesized that AZD4901 could reduce LH pulsa-
tility and prevent LH and possibly testosterone hyperse-
cretion in women with PCOS, and we investigated this
hypothesis in a randomized, multicenter clinical trial.
Materials and Methods
Study design and participants
This randomized, double-blind, double-dummy, placebo-
controlled, phase 2 trial (ClinicalTrials.gov identifier:
NCT01872078)was conductedbetween June2013andOctober
2014. Patients were competitively recruited in nine centers in
Germany, UK, and USA (Appendix 1). The study protocol was
reviewed and approved by the Institutional Review Board and
Ethics Committee governing each participating center, and the
study was conducted in accordance with the Declaration of
Helsinki.
Eligible patients were women aged 18–45 years with a body
mass index (BMI) of 18–40 kg/m2 and a clinical diagnosis of
PCOS; it was also a requirement that any confounding diagnosis
had been excluded by the investigator. Participants needed to
meet of all of the following criteria: (1) polycystic ovaries doc-
umented by ultrasound; (2) free testosterone85%of the upper
limit of reference range (measured within 21 days prior to ran-
domization at Arup Laboratories, USA. Reference range: 0.8–
7.4 pg/mL for women aged 18–30 years, 1.3–9.2 pg/mL for
women aged 31–40 years and 1.1–5.8 pg/mL for women aged
41–51 years); and (3) amenorrhea or oligomenorrhea (defined
as  6 menses per year).
Women who were not permanently or surgically sterile were
required to use effective nonhormonal methods of birth control,
such as strict abstinence or use of effective nonhormonal meth-
ods of birth control by the participant or their partner for the
duration of the study. Acceptable barrier methods of contracep-
tion included condom or occlusive cap (diaphragm or cervical/
vault caps) with spermicidal foam/gel/film/cream/suppository.
Patients were excluded if they had total testosterone serum
concentrations  5 nmol/L (as very high testosterone is often
associated with alternative diagnoses such an androgen-secret-
ing tumors), if they had serum follicle-stimulating hormone
(FSH) concentrations 10 IU/L (as a marker to exclude peri- or
postmenopause) (20), or if they had menstruated within the last
30 days.
Women with uncontrolled hypertension/diabetes, or signifi-
cant pulmonary, renal, hepatic, endocrine, or other systemic dis-
ease, or any other clinically relevant diseases or abnormalities as
judged by the investigator were also excluded in this early phase
clinical trial of an investigationalmedicinal product. In addition,
pregnant women and those not using adequate nonhormonal
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contraception were excluded. Full exclusion criteria are pre-
sented in Supplemental Table 1.
Randomization and masking
Participants were randomized equally to four treatment
groups: AZD490120mgonce daily (20mg/d), AZD490120mg
twice daily (40mg/d), AZD4901 40mg twice daily (80mg/d), or
placebo twice daily (Figure 1). These doses were selected based
on data from previous dose escalation studies, including those in
which ascending doses of AZD4901 up to 80 mg/d were admin-
istered to healthy volunteers. In these studies, significant LH and
testosterone suppression was seen at 40 mg/d, allowing a range
of safe doses to be included in this study to explore a dose-
response relationship.
Sequential randomization was carried out in each study cen-
ter by the investigator following a blinded computer-generated
randomization scheme produced byQuintiles Early Clinical De-
velopment (London, UK) using the AstraZeneca Global Ran-
domization system. To maintain study blinding, AZD4901
and/or matching placebo were administered such that two tab-
lets were taken twice daily by all participants. The first dose of
AZD4901or placebowas administered on themorning of day 1.
Participants were treated for 28 days.
Procedures and outcomes
The primary endpoint was the change from baseline in the
areaunder theLHplasmaconcentration–timecurveover8hours
postdose (AUC) on day 7 relative to placebo. Day 7 was selected
as the time point to evaluate LH because AZD4901 would have
achieved steady state and because any confounding that may
occur owing to a LH surge preceding spontaneous ovulation
would be avoided. Women who had menstruated in the 30 days
before the baseline visit (during which screening procedures and
laboratory tests were undertaken) were excluded.
Secondary objectives were to evaluate: (1) the change from
baseline in average total and free testosterone serum concentra-
tions over 8 hours postdose (Cavg) on days 7 and 28 relative to
placebo; (2) the safety and tolerability ofAZD4901; (3) thephar-
macokinetics of AZD4901 and its major metabolite
AZD12292232; and (4) the pharmacokinetic/pharmacody-
namic effect of AZD4901 on LH and testosterone concentra-
tions and on LH pulsatility parameters on days 7 and 28 relative
to placebo.
Several exploratory endpoints were investigated: (1) the
change from baseline in LH AUC on day 28 relative to placebo;
(2) changes from baseline in FSH, estradiol, progesterone, pro-
lactin, thyroid-stimulating hormone, and insulin-like growth
factor-1 on days 7 and 28; (3) glycated hemoglobin concentra-
tion on day 28; (4) the impact of AZD4901 on health-related
quality of life (HRQOL) from baseline to day 28; and (5) the
impact of AZD4901 on PCOS-specific patient-reported out-
comes as measured by changes from baseline on days 7, 14, 21,
and 28.
In addition, two post hoc exploratory analyses were carried
out to assess: (1) the absolute change from baseline in LH AUC:
FSH AUC ratio at days 7 and 28 relative to placebo; and (2) the
changes in LH AUC, total and free testosterone Cavg, and LH
pulsatility parameters relative to placebo in patients with no
biochemical evidence of ovulation (serum progesterone  6
ng/dL [19.1 nmol/L] at all study visits). Patients with no bio-
chemical evidence of ovulation are referred to as ‘nonovulating
patients’ hereafter.
LH pulsatility assessments were carried out using peripheral
venous blood samples collected at baseline and on days 7 and 28
at 10-minute intervals for 8 hours on these three days. FSH and
total and free testosterone concentrations were assessed using
samples collected at baseline and on days 7 and 28 before the
morning dose and then every hour for 8 hours. Estradiol, pro-
gesterone, prolactin, thyroid-stimulating hormone, insulin-like
growth factor, total and free thyroxin, and glycated hemoglobin
were measured using single samples collected at baseline and on
days 7 and 28. Analyses of total and free testosterone were per-
formed using high-performance liquid chromatography (HPLC)
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tandem mass spectrometry. All other endocrine markers were
analyzed immunometrically.
Samples for pharmacokinetic analysis were collected on days
7 and 28 before themorning dose and at 20minutes, 40minutes,
and 1, 1.5, 2, 3, 4, 6, and 8 hours postdose. Health-related qual-
ity of life (QOL) was assessed using the 36-item Short-Form
Health Survey (SF-36), completed by patients at baseline and on
day 28. Safety assessments included adverse event monitoring,
vital sign measurements, electrocardiograms, and physical ex-
amination. In addition, the Columbia-Suicide Severity Rating
Scale (C-SSRS) was used to identify any suicide-related adverse
events, including suicidal behavior and ideation, and was ad-
ministered at baseline and each visit throughout the study. The
C-SSRS was included because it had previously been mandated
by the US Food and Drug Administration for the early clinical
program of AZD4901 for the indication of schizophrenia.
Statistical methods
It was determined that a sample size of 48 patients (12 pa-
tients per treatment group) would be required to detect a 30%
change from baseline in LH AUC on day 7 relative to placebo
with 76% power at the two-sided 5% significance level. Allow-
ing for potential drop-outs, it was planned to randomize 56 pa-
tients to achieve 12 evaluable patients per group. A total of 67
patients were actually randomized, 65 of whomwere evaluable.
The dataset for analysis of pharmacodynamic parameters in-
cluded all patients who received at least one dose of study med-
ication (AZD4901 or placebo) and had appropriate pharmaco-
dynamicmeasurement. The safety dataset comprised all patients
who received at least one dose of studymedication and forwhom
some postdose data were available. The pharmacokinetic anal-
ysis set comprised patients who received at least one dose of
AZD4901 and had at least one postdose pharmacokinetic mea-
surement without important protocol deviations or violations
that could have affected the pharmacokinetic parameters
significantly.
All analyses were performed using a mixed-effects model for
repeated measures (MMRM) on change from baseline, with re-
peated-effects for day, fixed-effects for treatment, and treat-
ment-by-day interaction. No adjustments were made for
multiplicity.
LHAUCwas calculated by linear up/linear down trapezoidal
summationofobserved serumconcentrations.Data fromday–1,
7, and 28 samples collected outside a 2-minute collectionwin-
dow were not included in descriptive statistics for LH by time
point. LH AUC was calculated if there were no more than five
nonconsecutive missing values in the profile and no more than
three consecutive missing values (no more than two consecutive
missing values if one was at 0 or 8 hours). For LH AUC, com-
parisons between AZD4901 and placebo were performed using
aMMRMon the ln-transformed ratio to baseline, with ln-trans-
formed baseline LH AUC included as a covariate.
Data from day –1, 7, and 28 samples collected outside a 
10-minute collection window were not included in descriptive
statistics for total and free testosterone serum concentrations by
time. Total and free testosterone Cavg were calculated if there
were no more than two consecutive or nonconsecutive missing
values in the profile. If a value at 0 or 8 hours was missing, total
testosterone Cavg was imputed using the next or previously
scheduled value; free testosterone Cavg was not calculated if a
value at 0 or 8 hourswasmissing. For total and free testosterone,
comparisons between AZD4901 and placebo were performed
using a MMRM on the ln-transformed ratio to baseline, with
ln-transformed baseline Cavg included as a covariate.
Pharmacokinetic parameters were derived using standard
noncompartmental methods with WinNonlin Professional ver-
sion 6.3 (Pharsight Corp., Mountain View, CA, USA) and de-
scriptive statistics were reported. Descriptive statistics were also
reported for HRQOL individual scale scores and for adverse
events. Statistical analyseswere performedusing SAS version 9.4
(SAS Institute, Cary, NC, USA).
Results from theMMRManalyses using ln-transformed data
(eg, LH AUC) and nontransformed data (eg, number of pulses
per 8 hours) were reported using geometric and arithmetic
means, respectively.
LH pulsatility deconvolution analysis
The number of LHpulses, themass-per-pulse (MPP), and LH
basal secretion in8hourswerederivedusingdeconvolutionanal-
yses described previously (21, 22). Deconvolution estimates
were calculated if there were nomore than three nonconsecutive
missing values in the profile and no more than two consecutive
missing values in the profile. A MMRM on the ln-transformed
ratio to baseline values was used for comparisons between
AZD4901 and placebo for MMP and LH basal secretion, with
the ln-transformed baseline values included as a covariate. For
the number of pulses, comparisons between AZD4901 and pla-
cebo were carried out using a MMRM on the absolute change
from baseline, with the baseline value included as a covariate.
Results
Study population
Of the 403 women assessed for eligibility, 67 met the
inclusion criteria and were randomized to treatment; two
patients did not receive an interventionbecause of difficult
venous access, leaving 65 evaluable patients (Figure 1).
The most common reason for noneligibility was failure to
meet the screening criteria for free testosterone level (50%
of screen fails); around one third of screen fails did not
meet other laboratory inclusion parameters (most fre-
quently, minor abnormalities in alanine transaminase
and/or aspartate transaminase levels, iron-deficiency ane-
mia and rare cases of elevatedHbAlc), while the remainder
failed various clinical criteria including menstruation
within the last month and BMI. Of the 65 evaluable pa-
tients, 15 patients received AZD4901 20 mg/d, 17 re-
ceived AZD4901 40 mg/d, 17 received AZD4901 80
mg/d, and 16 received placebo. Demographic data and
baseline characteristics for these 65 patients are shown in
Table 1.
Primary endpoint
The baseline-adjusted changes of LH AUC at day 7 for
the AZD4901 groups relative to placebo are presented in
Figure 2A. In the AZD4901 80 mg/d group, there was a
baseline-adjusted reduction in LH AUC of 52.0% (95%
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CI: 29.6–67.3%; P  .0003) relative to placebo. There
was no evidence of an effect on LH AUC change from
baseline to day 7 relative to placebo for the lower
AZD4901 doses.
Table 1. Patient demographics and baseline characteristics
AZD4901 20
mg/day
AZD4901 40
mg/day
AZD4901 80
mg/day Placebo
(n  15) (n  17) (n  17) (n  16)
Age, yearsa 29 (6) 27 (6) 28 (6) 27 (3)
Height, cma 165.4 (6.2) 164.5 (8.1) 161.7 (4.5) 165.9 (7.4)
Weight, kga 85.8 (16.9) 84.2 (17.0) 85.2 (18.6) 87.9 (20.2)
BMI, kg/m2,a 31.1 (5.9) 30.8 (5.6) 32.2 (6.2) 31.9 (6.6)
Race, n (%)
White 15 (100.0) 13 (76.5) 11 (64.7) 14 (87.5)
Black or
African
American
0 (0.0) 3 (17.6) 3 (17.6) 1 (6.3)
Asian 0 (0.0) 0 (0.0) 2 (11.8) 0 (0.0)
Other 0 (0.0) 1 (5.9) 1 (5.9) 1 (6.3)
Ethnicity, n (%)
Hispanic 2 (13.3) 2 (11.8) 1 (5.9) 3 (18.8)
Non-Hispanic 13 (86.7) 15 (88.2) 16 (94.1) 13 (81.3)
Serum hormone Cavg
b
LH, IU/liter 9.78 (3.49) 9.12 (4.59) 9.22 (3.76) 9.09 (5.09)
FSH, IU/liter 6.15 (2.06) 4.57 (1.67) 4.52 (1.49) 4.68 (1.35)
Total
testosterone,
nmol/liter
1.96 (0.624) 2.07 (0.921) 2.25 (0.616) 1.68 (0.680)
Free
testosterone,
pmol/liter
66.3 (37.8) 72.3 (32.7) 91.9 (30.1) 84.5 (57.4)
Data are arithmetic mean (standard deviation) unless otherwise stated.
aAssessed during screening.
bAssessed at baseline.
Cavg, average concentration over 8 h; FSH, follicle-stimulating hormone; LH, luteinizing hormone.
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Secondary endpoints
Change in serum testosterone concentration
In the AZD4901 80 mg/d group, there was a baseline-
adjusted reduction in total testosterone Cavg of 28.7%
(95% CI: 13.9–40.9%; P  .0006) on day 7 relative to
placebo. A corresponding reduction in free testosterone
Cavg of 19.2% (95% CI: 0.14–34.62%; P  .0486) was
also observed in this group on day 7. Similarly to LH, no
significant reductions in testosterone concentrations from
baseline to day 7were observed in the groups receiving the
lower AZD4901 doses relative to the group receiving pla-
cebo (Figure 2C and Supplemental Table 2). Therewas no
evidence of an effect of any AZD4901 dose on total and
free testosterone concentrations at day 28 (Figure 2C and
Supplemental Table 2).
To explore the effect of AZD4901 on testosterone in
women who were considered to have no biochemical ev-
idence of ovulation in the study, a post hoc exploratory
analysis that excludedpatientswith serumprogesterone
6 ng/dL [19.1 nmol/L] (23) at any study visit was carried
out.Ninewomenwere considered tohaveovulatedduring
the study: three each in the AZD4901 20 mg/d and 80
mg/d groups, two in the AZD4901 40 mg/d group, and
one in the placebo group. When these women were ex-
cluded, the baseline-adjusted reductions in total testoster-
oneCavg frombaseline to days 7 and 28 relative to placebo
were 27.1% (95%CI: 13.3–38.7%) and 20.8% (95%CI:
5.3–33.8%), respectively, in theAZD490180mg/d group
(Figure 2D and Supplemental Table 2). Corresponding
reductions in free testosterone Cavg were 22.8% (95%CI:
6.8–36.0%) and 23.8% (95% CI: 7.3–37.3%) (Supple-
mental Table 2). The baseline characteristics of nonovu-
lating patients were not numerically different from that of
the whole cohort.
Luteinizing hormone pulsatility parameters
LH pulse frequency and LH basal secretion were sig-
nificantly reduced in the AZD4901 80mg/d group on day
7 relative to placebo. There was a greater decrease in the
number of LH pulses from baseline to day 7 in the
AZD4901 80mg/d group than in the placebo group, with
the difference being 3.55 (95% CI: 2.0–5.1) pulses/8
hours (Figure 3A and Supplemental Table 2). The reduc-
tion in LH basal secretion from baseline to day 7 relative
to placebowas 78.8% (95%CI: 53.6–90.3%) (Figure 3C
and Supplemental Table 2); mass-per-pulse remained un-
changed (Figure 3E and Supplemental Table 2). These ef-
fects persisted in nonovulating patients (Figure 3B and D
and Supplemental Table 2).
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Safety and tolerability
There was one serious adverse event reported in the
study: a case of appendicitis considered by the investigator
to be unrelated to treatment but which led to study dis-
continuation. This was the only adverse event that led to
discontinuation. Overall, adverse events were reported by
32 out of 49 patients receiving AZD4901 (65.3%) and 8
out of 16 patients receiving placebo (50.0%). The most
common preferred terms for adverse events reported by
patients were headache (reported by 14 patients [21.5%];
sixassessedby the investigators tobe related to treatment),
nasopharyngitis (reported by five patients [7.7%]; none
assessed by the investigators to be related to treatment)
and dizziness (reported by three patients [4.6%]; one as-
sessed by the investigators to be related to treatment). No
dose dependency was discernible in this small number of
events (Supplemental Table 5).
No patients reported suicidal ideation or behavior on
the C-SSRS questionnaire while receiving treatment or
during follow-up.
Pharmacokinetic endpoints
Circulating concentrations of AZD4901 and its active
metabolite increased in adose-dependentmanner thatwas
consistent with the previously reported pharmacokinetic
profile (19), and steady state was reached by day 7 (Sup-
plemental Table 3). AZD4901 was quickly absorbed fol-
lowing oral dosing; time to maximum concentration was
approximately 1.5–2 hours for all doses on days 7 and 28.
Exploratory endpoints
There was no evidence of an effect of AZD4901 on
changes in LH AUC from baseline to day 28 relative to
placebo (Figure 2A and Supplemental Table 2). In the post
hoc analysis, when considering only nonovulating pa-
tients, the change in LH AUC from baseline to day 28 in
the AZD4901 80 mg/d group was 34.9% (95% CI: 6.6–
54.6%) relative to placebo (Figure 2B and Supplemental
Table 2).
Relevant biochemical parameters are summarized in
Supplemental Table 4. FSH concentrations remained
largely unchanged in all treatment groups. Therefore,
given the changes in LH AUC, there was evidence of an
absolute reduction in the baseline-adjusted LHAUC:FSH
AUC ratio relative to placebo. Reductions relative to pla-
cebo were observed on day 7 (0.70; 95% CI: 0.23–1.17)
andday28 (0.72; 95%CI: 0.23–1.21) in theAZD490180
mg/d group. There was no evidence that the lower
AZD4901 doses had an effect on the LH AUC:FSH AUC
ratio relative placebo (Supplemental Table 2).
There was no evidence of an effect of AZD4901 on
HRQOL. Changes from baseline to day 28 across the
seven parameters of the SF-36 questionnaire were small
across the four treatment groups, and there were no ob-
vious trends (Supplemental Table 6).
Discussion
In this first study tomanipulate theNKB–GnRHpathway
in PCOS, the NK3 receptor antagonist AZD4901 specif-
ically reduced LH pulse frequency and, subsequently, se-
rum LH and testosterone concentrations. These reduc-
tions persisted innonovulatingpatients until the endof the
dosing period (day 28), although were not statistically
significant in the whole group. The duration of dosing in
this initial study was insufficient to assess the effect of
AZD4901 on clinical outcomes; longer trials with greater
patient numbers are needed to explore further the poten-
tial therapeutic role of AZD4901 in PCOS.
The present results are consistent with the hypothesis
that modulation of the GnRH axis by NK3 antagonism
using AZD4901 would decrease LH pulse frequency and
lower LH and testosterone concentrations in womenwith
PCOS. They are also consistent with previous data from
early clinical investigations of NK3 antagonists in indi-
viduals without an endocrine or reproductive disorder. In
these studies in healthy volunteers and patients with
schizophrenia, dose-dependent decrease in LH and testos-
terone concentrationswere observed (18). Taken together
with a central role of NKB in the regulation of GnRH and
LH pulse frequency, the present study demonstrates the
potential ofNKBantagonism to provide a novel approach
to treating the central neuroendocrine pathophysiology of
PCOS (ie, the LH hypersecretion that, in turn, drives an-
drogen excess).
In this study, reduction in overall LH secretion was
underpinned by reductions in LH pulsatility as well as in
basal LH secretion but not in the amount of LH secreted
per pulse. These findings are consistent with low LH pul-
satility observed in patients with genetic defects leading to
impairedNKB signaling (16). Therefore, the present study
contributes to the recent insights obtained into the regu-
lation of GnRH pulsatility following discoveries of hypo-
thalamic roles for kisspeptin and neurokinin B (13, 24,
25).
The observed reductions in LH and testosterone con-
centrations from baseline seen with the highest dose of
AZD4901 were statistically significant at day 7 for the
study population, but not at day 28. Reductions were,
however, statistically significant at day 28 in thosewomen
who did not ovulate during the study. This is because,
given the small sample size, the day 28 LH and testoster-
one results were confounded by what appeared to be a
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preovulatory LH surge in a small number of women; ex-
cluding women who had ovulated during the study from
the analysis resulted in themaintenance of the reduction in
LH and testosterone concentrations to day 28.
AZD4901 was well tolerated in patients with PCOS.
Most adverse events were considered unrelated to the
studymedication by the investigators, including the single
serious adverse event. Furthermore, given this class of
compounds was initially developed for the treatment of
schizophrenia, it is reassuring to note that questionnaires
assessing participant well-being (SF-36 and C-SSRS) did
not show any signals of concern.
Currently, while several medications are used to treat
PCOS and its symptoms, there is no treatment with spe-
cific regulatory approval for PCOS, and there are very few
new molecular entities in clinical development for this
condition (8). Hence, a range of agents such as spirono-
lactone, GnRH modulators, metformin, oral contracep-
tive (OC) pills and clomiphene are used to manage the
symptoms and associated health complications of PCOS
(6), reflecting the multifactorial etiology of the condition
(9–11). The results from this study, if consistently repro-
duced in subsequent clinical studies, suggest that
AZD4901 has the potential to emerge as a novel therapy
for PCOS and to complement recent developments in the
treatment of anovulatory infertility in women with PCOS
(26).
The present study has clear strengths such as the inclu-
sion of detailed LH pulse profiling and the use of placebo
control to estimate placebo-adjusted changes from base-
line hormones.Only the highest dose administered elicited
a significant response in our study, suggesting thatwemay
not have reached maximal response in this PCOS popu-
lation and that testing doses higher than 80mg/d in future
studies may be warranted, a point supported by the safety
and tolerability profile of AZD4901 in the present study.
BeforeAZD4901 canbe developed as a therapy for PCOS,
longer studies assessing clinical outcomes (eg, ovulation
and hirsutism) and quantification of potential metabolic
improvements in larger populations, as well as potential
compensatory mechanisms, are needed.
Because thiswas a phase 2a trial aimed at validating the
concept, our focus was on biomarkers such as LH and
testosterone; the duration of treatment was insufficient to
assess the effects on clinical endpoints such as ovulation.
A small numberofpatients appear tohaveovulatedduring
the trial, based on random serumprogesterone 6 ng/mL
(19.1 nmol/L), which is consistent with clinical practice
recommendations (23) and previous data (27). A total of
nine women ovulated, three each in the 20 mg/d and 80
mg/d groups, two in the 40 mg/d group, and one in the
placebo group. These small numbers did not allow us to
make any meaningful comparisons between groups, or
between ovulators and nonovulators. While the observed
ovulation rates suggested by elevation of serum proges-
terone concentration (particularly among treated pa-
tients) may be higher during our study than expected for
PCOS patients in general, their possible relationship to
treatment cannot be firmly concluded for at least two rea-
sons: firstly, the small numbers of ovulating patients ob-
served do not allow statistically rigorous comparisons
among groups; secondly, the timing of ovulation within
the study appeared to differ across the nine women but
serum progesterone measurements were only taken at
baseline and days 7, 28 and 42, so the day of ovulation
cannot be precisely identified. Both reasons reflect the fact
that this early study was designed and powered to achieve
a different primary endpoint. Given the clinical impor-
tance of menstrual irregularity in PCOS, ovulation needs
to be characterized further in future longer-term studies
using self-reported menstruation (eg, menstrual diary),
biomarkers (eg, LH, estradiol), and/or ultrasonography
over multiple cycles.
The results of our study also have implications for
wider research into new therapies for patients with PCOS.
First, the heterogeneity of the PCOS phenotype presents a
challenge to attaining adequate power in early-phase ran-
domized controlled trials. We addressed this by selecting
a hyperandrogenemic population with polycystic ovarian
morphology and menstrual irregularity. Such an ap-
proach, however, required the screening of well over 400
women to recruit 67 participants. Furthermore, the gen-
eralizability of our results to nonhyperandrogenemic pa-
tients with PCOS requires further study.
Finally, it has to be emphasized that the present study
is a clinical trial of a pharmacological agent; therefore,
inferences on the etiology of PCOS and the multifactorial
nature of the mechanism by which LH pulse frequency
becomes increased cannot bedrawn from thepresent data.
In conclusion, this is the first clinical study to manip-
ulate the hypothalamic kisspeptin-NKB–GnRH pathway
in women with PCOS. The NK3 receptor antagonist
AZD4901 reduced serum LH pulse frequency and, sub-
sequently, serum LH and testosterone concentrations.
These findings demonstrate the potential for NKB antag-
onism to provide a novel therapeutic approach by target-
ing the neuroendocrine pathophysiology in PCOS.
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